HUE026210T2 - Procedure for serum-free, insulin-free VII. factor - Google Patents
Procedure for serum-free, insulin-free VII. factor Download PDFInfo
- Publication number
- HUE026210T2 HUE026210T2 HUE09826577A HUE09826577A HUE026210T2 HU E026210 T2 HUE026210 T2 HU E026210T2 HU E09826577 A HUE09826577 A HU E09826577A HU E09826577 A HUE09826577 A HU E09826577A HU E026210 T2 HUE026210 T2 HU E026210T2
- Authority
- HU
- Hungary
- Prior art keywords
- medium
- insulin
- free
- cells
- culture
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 233
- 229940012413 factor vii Drugs 0.000 title abstract description 194
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 470
- 210000004027 cell Anatomy 0.000 claims abstract description 325
- 102000004877 Insulin Human genes 0.000 claims abstract description 238
- 108090001061 Insulin Proteins 0.000 claims abstract description 238
- 229940125396 insulin Drugs 0.000 claims abstract description 235
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims abstract description 106
- 238000004519 manufacturing process Methods 0.000 claims abstract description 56
- 241000699802 Cricetulus griseus Species 0.000 claims abstract description 10
- 239000002609 medium Substances 0.000 claims description 193
- 230000008569 process Effects 0.000 claims description 97
- 229920001184 polypeptide Polymers 0.000 claims description 64
- 230000012010 growth Effects 0.000 claims description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 53
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 53
- 239000000969 carrier Substances 0.000 claims description 35
- 230000010412 perfusion Effects 0.000 claims description 25
- 238000004113 cell culture Methods 0.000 claims description 24
- 238000010923 batch production Methods 0.000 claims description 22
- 239000001963 growth medium Substances 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 20
- 230000000644 propagated effect Effects 0.000 claims description 19
- 239000000725 suspension Substances 0.000 claims description 16
- 239000012737 fresh medium Substances 0.000 claims description 15
- 238000003306 harvesting Methods 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 13
- 230000001902 propagating effect Effects 0.000 claims description 11
- 238000012546 transfer Methods 0.000 claims description 9
- 238000004062 sedimentation Methods 0.000 claims description 8
- 238000004114 suspension culture Methods 0.000 claims description 7
- 230000006978 adaptation Effects 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 238000011031 large-scale manufacturing process Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 239000002054 inoculum Substances 0.000 claims description 4
- 230000007774 longterm Effects 0.000 claims description 4
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 230000002608 insulinlike Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 239000006228 supernatant Substances 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 235000016623 Fragaria vesca Nutrition 0.000 claims 1
- 240000009088 Fragaria x ananassa Species 0.000 claims 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 241000307523 Xenostegia media Species 0.000 claims 1
- NJFMNPFATSYWHB-UHFFFAOYSA-N ac1l9hgr Chemical compound [Fe].[Fe] NJFMNPFATSYWHB-UHFFFAOYSA-N 0.000 claims 1
- 239000010426 asphalt Substances 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 238000009395 breeding Methods 0.000 claims 1
- 230000001488 breeding effect Effects 0.000 claims 1
- 239000006229 carbon black Substances 0.000 claims 1
- 210000000078 claw Anatomy 0.000 claims 1
- 239000004927 clay Substances 0.000 claims 1
- 239000003245 coal Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 239000010978 jasper Substances 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000010309 melting process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 108010016297 plasmin drug combination deoxyribonuclease Proteins 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000007320 rich medium Substances 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 102100023804 Coagulation factor VII Human genes 0.000 abstract description 194
- 108010023321 Factor VII Proteins 0.000 abstract description 194
- 238000012258 culturing Methods 0.000 abstract description 19
- 239000004017 serum-free culture medium Substances 0.000 abstract description 19
- 239000000203 mixture Substances 0.000 abstract description 12
- 229940099816 human factor vii Drugs 0.000 abstract description 6
- 210000001672 ovary Anatomy 0.000 abstract description 5
- 238000011218 seed culture Methods 0.000 description 21
- 230000003698 anagen phase Effects 0.000 description 16
- 239000000306 component Substances 0.000 description 14
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 14
- 108010000499 Thromboplastin Proteins 0.000 description 13
- 102000002262 Thromboplastin Human genes 0.000 description 13
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 11
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 11
- 235000019175 phylloquinone Nutrition 0.000 description 11
- 239000011772 phylloquinone Substances 0.000 description 11
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 11
- 229960001898 phytomenadione Drugs 0.000 description 11
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 10
- 210000004962 mammalian cell Anatomy 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 9
- 108010013773 recombinant FVIIa Proteins 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 108010014173 Factor X Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 5
- 239000005700 Putrescine Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 4
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 108010048049 Factor IXa Proteins 0.000 description 3
- 108010074860 Factor Xa Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 231100000319 bleeding Toxicity 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- -1 for example Chemical compound 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N vitamin K3 Natural products C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100391171 Schizosaccharomyces pombe (strain 972 / ATCC 24843) for3 gene Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000897276 Termes Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 230000035071 co-translational protein modification Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000007386 factor VII deficiency Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940103453 novolin Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11379208P | 2008-11-12 | 2008-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE026210T2 true HUE026210T2 (en) | 2016-05-30 |
Family
ID=42165541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE09826577A HUE026210T2 (en) | 2008-11-12 | 2009-11-05 | Procedure for serum-free, insulin-free VII. factor |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100120093A1 (https=) |
| EP (2) | EP2356247B2 (https=) |
| JP (1) | JP5719301B2 (https=) |
| AU (1) | AU2009314345B2 (https=) |
| CA (1) | CA2742107A1 (https=) |
| DK (1) | DK2356247T4 (https=) |
| ES (1) | ES2547881T5 (https=) |
| HK (1) | HK1219113A1 (https=) |
| HR (1) | HRP20151054T4 (https=) |
| HU (1) | HUE026210T2 (https=) |
| IL (1) | IL212355A (https=) |
| PL (1) | PL2356247T5 (https=) |
| PT (1) | PT2356247E (https=) |
| SI (1) | SI2356247T2 (https=) |
| WO (1) | WO2010056584A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013535981A (ja) * | 2010-08-20 | 2013-09-19 | ワイス・エルエルシー | 成長因子不含適合細胞の細胞培養 |
| US20120076779A1 (en) | 2010-09-17 | 2012-03-29 | Baxter Healthcare S.A. | STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| KR20150026024A (ko) * | 2013-08-30 | 2015-03-11 | 한미약품 주식회사 | 인간 혈액응고 7인자 유도체의 대량 생산 방법 |
| US11286292B2 (en) | 2014-02-07 | 2022-03-29 | Cmc Biologics A/S | Bioreactor arrangement and continuous process for producing and capturing a biopolymer |
| NZ724826A (en) * | 2014-04-16 | 2022-07-29 | Cmc Biologics As | A high cell density fill and draw fermentation process |
| AU2015269365A1 (en) | 2014-06-04 | 2016-12-15 | Amgen Inc. | Methods for harvesting mammalian cell cultures |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| GB9022545D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
| US5804420A (en) * | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| AT409379B (de) † | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| DK1200561T3 (da) † | 1999-08-05 | 2006-10-16 | Baxter Ag | Rekombinant stabil celleklon, dens fremstilling og anvendelse |
| US20030204338A1 (en) | 2002-04-22 | 2003-10-30 | Peter Martinek | Method and measurement probe for the performance of measurements in water supply systems |
| US20040185535A1 (en) † | 2003-03-21 | 2004-09-23 | Giles Wilson | Industrial-scale serum-free production of recombinant FVII in mammalian cells |
| BR0114373A (pt) * | 2000-10-02 | 2004-02-17 | Novo Nordisk As | Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante |
| EP1434857B1 (en) * | 2001-10-02 | 2007-08-01 | Novo Nordisk Health Care AG | Method for production of recombinant proteins in eukaryote cells |
| US20050214289A1 (en) * | 2004-03-26 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies against Nogo receptor |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| EP1851305B1 (en) * | 2005-02-11 | 2012-01-18 | Novo Nordisk Health Care AG | Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate |
| CN101300342A (zh) † | 2005-11-02 | 2008-11-05 | 惠氏公司 | 用于使哺乳动物细胞具备适应性的方法 |
| ES2474573T3 (es) † | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
-
2009
- 2009-11-05 PT PT98265770T patent/PT2356247E/pt unknown
- 2009-11-05 WO PCT/US2009/063338 patent/WO2010056584A1/en not_active Ceased
- 2009-11-05 EP EP09826577.0A patent/EP2356247B2/en not_active Not-in-force
- 2009-11-05 JP JP2011535656A patent/JP5719301B2/ja active Active
- 2009-11-05 CA CA2742107A patent/CA2742107A1/en not_active Abandoned
- 2009-11-05 EP EP15169975.8A patent/EP2977461A1/en not_active Withdrawn
- 2009-11-05 ES ES09826577T patent/ES2547881T5/es active Active
- 2009-11-05 HU HUE09826577A patent/HUE026210T2/en unknown
- 2009-11-05 SI SI200931283T patent/SI2356247T2/sl unknown
- 2009-11-05 PL PL09826577T patent/PL2356247T5/pl unknown
- 2009-11-05 HR HRP20151054T patent/HRP20151054T4/hr unknown
- 2009-11-05 US US12/612,752 patent/US20100120093A1/en not_active Abandoned
- 2009-11-05 AU AU2009314345A patent/AU2009314345B2/en not_active Ceased
- 2009-11-05 DK DK09826577.0T patent/DK2356247T4/da active
-
2011
- 2011-04-14 IL IL212355A patent/IL212355A/en not_active IP Right Cessation
-
2016
- 2016-06-14 HK HK16106839.4A patent/HK1219113A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2356247T5 (pl) | 2019-10-31 |
| SI2356247T1 (sl) | 2015-11-30 |
| HK1219113A1 (en) | 2017-03-24 |
| PT2356247E (pt) | 2015-10-26 |
| CA2742107A1 (en) | 2010-05-20 |
| EP2977461A1 (en) | 2016-01-27 |
| JP2012508562A (ja) | 2012-04-12 |
| IL212355A0 (en) | 2011-06-30 |
| US20100120093A1 (en) | 2010-05-13 |
| JP5719301B2 (ja) | 2015-05-13 |
| ES2547881T5 (es) | 2019-10-16 |
| AU2009314345B2 (en) | 2015-02-12 |
| EP2356247A4 (en) | 2013-01-02 |
| PL2356247T3 (pl) | 2016-04-29 |
| WO2010056584A1 (en) | 2010-05-20 |
| SI2356247T2 (sl) | 2019-08-30 |
| EP2356247A1 (en) | 2011-08-17 |
| IL212355A (en) | 2016-04-21 |
| HRP20151054T4 (hr) | 2019-11-15 |
| EP2356247B2 (en) | 2019-05-15 |
| EP2356247B1 (en) | 2015-07-15 |
| HRP20151054T1 (xx) | 2015-11-20 |
| ES2547881T3 (es) | 2015-10-09 |
| AU2009314345A1 (en) | 2011-06-30 |
| DK2356247T3 (en) | 2015-09-21 |
| DK2356247T4 (da) | 2019-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE026210T2 (en) | Procedure for serum-free, insulin-free VII. factor | |
| EP1325147A2 (en) | Industrial-scale serum-free production of recombinant factor vii in mammalian cells | |
| Avgerinos et al. | Spin filter perfusion system for high density cell culture: production of recombinant urinary type plasminogen activator in CHO cells | |
| ES2291534T3 (es) | Metodo para la produccion de proteinas recombinantes en celulas eucariotas. | |
| US20090263866A1 (en) | Industrial-scale Serum-free Production of Recombinant Factor VII in Mammalian Cells | |
| EP3207132B1 (en) | Methods of shifting an isoelectric profile of a protein product and uses thereof | |
| KR102568951B1 (ko) | 포유류 세포의 배양 방법 | |
| EA023193B1 (ru) | Среда для культивирования клеток для экспрессии белков adamts | |
| IL234890A (en) | Process for the culturing of cells | |
| JP5806465B2 (ja) | 実質的に動物性タンパク質を含まない組換えフリンおよび実質的に動物性タンパク質を含まない組換えフリンを作製するための方法 | |
| JP2003506077A (ja) | 組換え安定細胞クローン、その産生およびその使用 | |
| KR20230170728A (ko) | 포유류 세포의 관류 배양 방법 | |
| AU2013203993B2 (en) | Process for cell culturing by continuous perfusion and alternating tangential flow | |
| US20090075331A1 (en) | Industrial-scale serum-free production of recombinant proteins in mammalian cells | |
| JPH05207874A (ja) | 無血清培地 | |
| JPH05192135A (ja) | 動物細胞の担体からの剥離及び移植方法 | |
| JPH05207875A (ja) | 無血清培地 | |
| JP2011004754A (ja) | 組換え安定細胞クローン、その産生およびその使用 | |
| JP2010099093A (ja) | 組換え安定細胞クローン、その産生およびその使用 |